Validation and Application of a Module of the M. D. Anderson Symptom Inventory for Measuring Multiple Symptoms in Patients With Gastrointestinal Cancer (the MDASI-GI)
被引:98
|
作者:
Wang, Xin Shelley
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
Wang, Xin Shelley
[1
]
Williams, Loretta A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
Williams, Loretta A.
[1
]
Eng, Cathy
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
Eng, Cathy
[2
]
Mendoza, Tito R.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
Mendoza, Tito R.
[1
]
Shah, Nyma A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
Shah, Nyma A.
[1
]
Kirkendoll, Karyn J.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
Kirkendoll, Karyn J.
[1
]
Shah, Pankil K.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
Shah, Pankil K.
[1
]
Trask, Peter C.
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Inc, Global Outcomes Res, New London, CT USAUniv Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
Trask, Peter C.
[3
]
Palos, Guadalupe R.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
Palos, Guadalupe R.
[1
]
Cleeland, Charles S.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USAUniv Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
Cleeland, Charles S.
[1
]
机构:
[1] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[3] Pfizer Inc, Global Outcomes Res, New London, CT USA
cancer;
symptoms;
assessment;
validation;
gastrointestinal;
M. D. Anderson Symptom Inventory;
REPORTED OUTCOMES;
INSTRUMENT;
DISTRESS;
PREVALENCE;
BURDEN;
D O I:
10.1002/cncr.24920
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
The M. D. Anderson Symptom Inventory (MDASI) was developed as a brief yet comprehensive tool to assess patient-reported symptom severity and interference in patients with cancer. The authors report the development of an MDASI module for use in patients with gastrointestinal (GI) cancer (the MDASI-GI). METHODS: Patients with GI cancer (N = 184) participated in module development and validation. The process included: 1) generating GI-specific candidate items with input from GI oncologists and from qualitative interviews with patients and adding those items to the core MDASI for testing; 2) dropping candidate GI items that lacked sensitivity; 3) validating the psychometric properties (validity, reliability, sensitivity) of the resulting MDASI-GI; and 4) conducting cognitive debriefing interviews with patients to confirm the questionnaire's ease of comprehension, relevance, and acceptability. RESULTS: Five GI-specific symptom items (constipation, diarrhea, difficulty swallowing, change in taste, and feeling bloated) were added to the original 19 MDASI symptom and interference items to form the MDASI-GI. Sixty-one percent of the sample had 1 or more moderate-to-severe symptom(s) (>= 5 on a severity scale from 0 to 10). Cronbach a values were .80 and .87 for symptom severity items and interference items, respectively. Known-group validity (sensitivity) was supported by the ability of the MDASI-GI to detect significant differences in symptom and interference levels according to performance status (P < .001). Cognitive debriefing demonstrated that for patients, the MDASI-GI was an easy-to-use and understandable tool. CONCLUSIONS: The current results indicated that the MDASI-GI is a valid, reliable, and concise tool for measuring symptom severity and interference with function in patients with GI cancer. Cancer 2010;116:2053-63. (c) 2010 American Cancer Society.